Recursion Pharmaceuticals, Inc. RXRX Business Segments — Discovery
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept rxrx:DiscoveryExpense.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s business segments — discovery.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s business segments — discovery?
- Recursion Pharmaceuticals, Inc. (RXRX) reported business segments — discovery of $6.33M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s business segments — discovery changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s business segments — discovery increased by 0.7% year-over-year, from $6.29M to $6.33M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s business segments — discovery?
- Over 3 years (2022 to 2025), Recursion Pharmaceuticals, Inc.'s business segments — discovery has grown at a 51.1% compound annual growth rate (CAGR), from $19.77M to $68.19M.
- What does business segments — discovery mean?
- Measures the financial resources allocated to early-stage research and discovery activities aimed at identifying new product candidates or intellectual property. This metric reflects the company's commitment to long-term innovation and the health of its future product pipeline.